Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Aug 1, 2012)
  • 8-K (Jul 20, 2012)
  • 8-K (Jul 12, 2012)
  • 8-K (Jul 2, 2012)
  • 8-K (Jun 28, 2012)
  • 8-K (Jun 4, 2012)

 
Other

Medtox Scientific 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1
form8-k020912.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 9, 2012
 

 
MEDTOX SCIENTIFIC, INC.
 (Exact name of registrant as specified in its charter)
 

         
Delaware
 
1-11394
 
95-3863205
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 

 
     
402 West County Road D, St. Paul, Minnesota
 
55112
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (651) 636-7466
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

 

Item 2.02.                      Results of Operations and Financial Condition

On February 9, 2012, MEDTOX Scientific, Inc. announced results for the fourth quarter and year-ended December 31, 2011, as described in the press release attached as Exhibit 99.1.


 
2

 

Item 9.01.                      Financial Statements and Exhibits.
 
 
(c)
Exhibits.
 
The following exhibit is filed as part of this report:
 
     
Exhibit No.
 
Description
99.1
 
MEDTOX Scientific, Inc. Press Release, dated February 9, 2012.
 


 
3

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


MEDTOX Scientific, Inc.




Date:  February 9, 2012                                                                        By:       /s/ Richard J. Braun                           
Name:  Richard J. Braun
Title:    Chief Executive Officer
 
 
 
4

 

INDEX TO EXHIBITS

 
     
Exhibit No.
 
Description
99.1
 
MEDTOX Scientific, Inc. Press Release, dated February 9, 2012.
 
 
 
 
 

5


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki